PI3K抑制剂-话题@MedSci

#PI3K抑制剂#

14篇内容 | 1398人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2124086, encodeId=25be212408609, content=<a href='/topic/show?id=f336e29134' target=_blank style='color:#2F92EE;'>#FDA#</a>已经批准<a href='/topic/show?id=37121425067' target=_blank style='color:#2F92EE;'>#PI3K抑制剂#</a><a href='/topic/show?id=0b171058161e' target=_blank style='color:#2F92EE;'>#leniolisib#</a>上市，用于<a href='/topic/show?id=b8e410581e16' target=_blank style='color:#2F92EE;'>#磷脂酰肌醇3-激酶δ综合征#</a>, objectTitle=FDA已经批准PI3K抑制剂leniolisib上市，用于磷脂酰肌醇3-激酶δ综合征, objectType=article, longId=765735, objectId=a4f7e65735ed, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230313/2dd597e188a74669ae95e2f2607d674c.jpg, objectUrl=/article/show_article.do?id=a4f7e65735ed, replyNumber=0, likeNumber=123, createdTime=2023-04-06, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a4f7e65735ed, moduleTitle=FDA已经批准PI3K抑制剂leniolisib上市，用于磷脂酰肌醇3-激酶δ综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4f7e65735ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536887, encodeId=24a5153688ed6, content=<a href='/topic/show?id=37121425067' target=_blank style='color:#2F92EE;'>#PI3K抑制剂#</a>, objectTitle=Nat Rev Drug Discov：PI3K抑制剂即将迎来大爆发, objectType=article, longId=213099, objectId=5d892130997b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d892130997b, replyNumber=0, likeNumber=113, createdTime=2021-06-25, rootId=0, userName=bbjsj_1983, userId=477612737263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d892130997b, moduleTitle=Nat Rev Drug Discov：PI3K抑制剂即将迎来大爆发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d892130997b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536886, encodeId=f082153688602, content=<a href='/topic/show?id=37121425067' target=_blank style='color:#2F92EE;'>#PI3K抑制剂#</a>, objectTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, objectType=article, longId=202384, objectId=f40b202384ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f40b202384ce, replyNumber=0, likeNumber=69, createdTime=2020-10-24, rootId=0, userName=bbjsj_1983, userId=477612737263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f40b202384ce, moduleTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f40b202384ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536885, encodeId=572f153688547, content=<a href='/topic/show?id=37121425067' target=_blank style='color:#2F92EE;'>#PI3K抑制剂#</a>, objectTitle=Clin Cancer Res：Ribociclib+氟维司群±PI3K抑制剂治疗HR+晚期乳腺癌, objectType=article, longId=200289, objectId=3ac1200289a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ac1200289a6, replyNumber=0, likeNumber=72, createdTime=2020-09-06, rootId=0, userName=bbjsj_1983, userId=477612737263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ac1200289a6, moduleTitle=Clin Cancer Res：Ribociclib+氟维司群±PI3K抑制剂治疗HR+晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ac1200289a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536884, encodeId=330915368848c, content=<a href='/topic/show?id=37121425067' target=_blank style='color:#2F92EE;'>#PI3K抑制剂#</a>, objectTitle=Verastem的PI3K抑制剂COPIKTRA治疗T细胞淋巴瘤，获得FDA的孤儿药称号, objectType=article, longId=180514, objectId=7f23180514e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f23180514e5, replyNumber=0, likeNumber=72, createdTime=2019-10-06, rootId=0, userName=bbjsj_1983, userId=477612737263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f23180514e5, moduleTitle=Verastem的PI3K抑制剂COPIKTRA治疗T细胞淋巴瘤，获得FDA的孤儿药称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f23180514e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536883, encodeId=61e31536883b5, content=<a href='/topic/show?id=37121425067' target=_blank style='color:#2F92EE;'>#PI3K抑制剂#</a>, objectTitle=**乳腺癌PI3K抑制剂Alpelisib上市，诺华开启乳腺癌分子分型新时代, objectType=article, longId=177001, objectId=9f851e70016d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f851e70016d, replyNumber=0, likeNumber=75, createdTime=2019-08-07, rootId=0, userName=bbjsj_1983, userId=477612737263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f851e70016d, moduleTitle=**乳腺癌PI3K抑制剂Alpelisib上市，诺华开启乳腺癌分子分型新时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f851e70016d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536882, encodeId=70e81536882e5, content=<a href='/topic/show?id=37121425067' target=_blank style='color:#2F92EE;'>#PI3K抑制剂#</a>, objectTitle=拜耳PI3K抑制剂Aliqopa治疗惰性非霍奇金淋巴瘤，获FDA的突破性治疗指定, objectType=article, longId=167490, objectId=8d7f16e4907c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d7f16e4907c, replyNumber=0, likeNumber=65, createdTime=2019-06-03, rootId=0, userName=bbjsj_1983, userId=477612737263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d7f16e4907c, moduleTitle=拜耳PI3K抑制剂Aliqopa治疗惰性非霍奇金淋巴瘤，获FDA的突破性治疗指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d7f16e4907c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536881, encodeId=d34315368815f, content=<a href='/topic/show?id=37121425067' target=_blank style='color:#2F92EE;'>#PI3K抑制剂#</a>, objectTitle=晚期乳腺癌：诺华公司的PI3K抑制剂Piqray获FDA授权, objectType=article, longId=166798, objectId=fe2e166e985f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe2e166e985f, replyNumber=0, likeNumber=81, createdTime=2019-05-27, rootId=0, userName=bbjsj_1983, userId=477612737263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe2e166e985f, moduleTitle=晚期乳腺癌：诺华公司的PI3K抑制剂Piqray获FDA授权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe2e166e985f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536880, encodeId=75861536880e3, content=<a href='/topic/show?id=37121425067' target=_blank style='color:#2F92EE;'>#PI3K抑制剂#</a>, objectTitle=PI3K抑制剂的临床发展：旨在改善对实体瘤的治疗效果, objectType=article, longId=164853, objectId=1fc0164853ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fc0164853ad, replyNumber=0, likeNumber=85, createdTime=2019-04-24, rootId=0, userName=bbjsj_1983, userId=477612737263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fc0164853ad, moduleTitle=PI3K抑制剂的临床发展：旨在改善对实体瘤的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fc0164853ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536879, encodeId=37e715368e987, content=<a href='/topic/show?id=37121425067' target=_blank style='color:#2F92EE;'>#PI3K抑制剂#</a>, objectTitle=Science：雌激素受体（ER）阳性乳腺癌抵抗PI3K抑制剂疗法的原因, objectType=article, longId=93347, objectId=0be19334e37, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0be19334e37, replyNumber=0, likeNumber=87, createdTime=2017-03-26, rootId=0, userName=bbjsj_1983, userId=477612737263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0be19334e37, moduleTitle=Science：雌激素受体（ER）阳性乳腺癌抵抗PI3K抑制剂疗法的原因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0be19334e37)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536878, encodeId=69c515368e889, content=<a href='/topic/show?id=37121425067' target=_blank style='color:#2F92EE;'>#PI3K抑制剂#</a>, objectTitle=PNAS：“救命药”竟成“夺命药”——PI3K抑制剂促进癌转移, objectType=article, longId=52908, objectId=67e952908da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67e952908da, replyNumber=0, likeNumber=64, createdTime=2015-07-07, rootId=0, userName=bbjsj_1983, userId=477612737263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67e952908da, moduleTitle=PNAS：“救命药”竟成“夺命药”——PI3K抑制剂促进癌转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67e952908da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536877, encodeId=df1b15368e724, content=<a href='/topic/show?id=37121425067' target=_blank style='color:#2F92EE;'>#PI3K抑制剂#</a>, objectTitle=SABCS 2014：PI3K抑制剂用于ER阳性AI耐药的晚期乳腺癌, objectType=article, longId=44407, objectId=20064440e2c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20064440e2c, replyNumber=0, likeNumber=92, createdTime=2014-12-24, rootId=0, userName=bbjsj_1983, userId=477612737263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20064440e2c, moduleTitle=SABCS 2014：PI3K抑制剂用于ER阳性AI耐药的晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20064440e2c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536876, encodeId=6a4415368e697, content=<a href='/topic/show?id=37121425067' target=_blank style='color:#2F92EE;'>#PI3K抑制剂#</a>, objectTitle=Gastroenterology:PI3K抑制剂和5-氟尿嘧啶有不同疗效的胃癌分子亚型, objectType=article, longId=23917, objectId=0ae62391e12, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ae62391e12, replyNumber=0, likeNumber=97, createdTime=2013-09-07, rootId=0, userName=bbjsj_1983, userId=477612737263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ae62391e12, moduleTitle=Gastroenterology:PI3K抑制剂和5-氟尿嘧啶有不同疗效的胃癌分子亚型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ae62391e12)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1536875, encodeId=833715368e564, content=<a href='/topic/show?id=37121425067' target=_blank style='color:#2F92EE;'>#PI3K抑制剂#</a>, objectTitle=PI3K抑制剂局部给药可防治急性肺损伤, objectType=article, longId=3162, objectId=f04331627e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f04331627e, replyNumber=0, likeNumber=83, createdTime=2011-10-11, rootId=0, userName=bbjsj_1983, userId=477612737263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f04331627e, moduleTitle=PI3K抑制剂局部给药可防治急性肺损伤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f04331627e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PI3K抑制剂

2020-05-29

侠胆医心 (审核中...)

前往app查看评论内容

#FDA#已经批准#PI3K抑制剂##leniolisib#上市，用于#磷脂酰肌醇3-激酶δ综合征#

FDA已经批准PI3K抑制剂leniolisib上市，用于磷脂酰肌醇3-激酶δ综合征

2023-04-06发表于上海

bbjsj_1983 (审核中...)

前往app查看评论内容

#PI3K抑制剂#

Nat Rev Drug Discov：PI3K抑制剂即将迎来大爆发

2021-06-25

bbjsj_1983 (审核中...)

前往app查看评论内容

#PI3K抑制剂#

CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定

2020-10-24

bbjsj_1983 (审核中...)

前往app查看评论内容

#PI3K抑制剂#

Clin Cancer Res：Ribociclib+氟维司群±PI3K抑制剂治疗HR+晚期乳腺癌

2020-09-06

bbjsj_1983 (审核中...)

前往app查看评论内容

#PI3K抑制剂#

Verastem的PI3K抑制剂COPIKTRA治疗T细胞淋巴瘤，获得FDA的孤儿药称号

2019-10-06

bbjsj_1983 (审核中...)

前往app查看评论内容

#PI3K抑制剂#

**乳腺癌PI3K抑制剂Alpelisib上市，诺华开启乳腺癌分子分型新时代

2019-08-07

bbjsj_1983 (审核中...)

前往app查看评论内容

#PI3K抑制剂#

拜耳PI3K抑制剂Aliqopa治疗惰性非霍奇金淋巴瘤，获FDA的突破性治疗指定

2019-06-03

bbjsj_1983 (审核中...)

前往app查看评论内容

#PI3K抑制剂#

晚期乳腺癌：诺华公司的PI3K抑制剂Piqray获FDA授权

2019-05-27

bbjsj_1983 (审核中...)

前往app查看评论内容

#PI3K抑制剂#

PI3K抑制剂的临床发展：旨在改善对实体瘤的治疗效果

2019-04-24

bbjsj_1983 (审核中...)

前往app查看评论内容

#PI3K抑制剂#

Science：雌激素受体（ER）阳性乳腺癌抵抗PI3K抑制剂疗法的原因

2017-03-26

bbjsj_1983 (审核中...)

前往app查看评论内容

#PI3K抑制剂#

PNAS：“救命药”竟成“夺命药”——PI3K抑制剂促进癌转移

2015-07-07

bbjsj_1983 (审核中...)

前往app查看评论内容

#PI3K抑制剂#

SABCS 2014：PI3K抑制剂用于ER阳性AI耐药的晚期乳腺癌

2014-12-24

bbjsj_1983 (审核中...)

前往app查看评论内容

#PI3K抑制剂#

Gastroenterology:PI3K抑制剂和5-氟尿嘧啶有不同疗效的胃癌分子亚型

2013-09-07

bbjsj_1983 (审核中...)

前往app查看评论内容

#PI3K抑制剂#

PI3K抑制剂局部给药可防治急性肺损伤

2011-10-11

科室
- - 订阅+
  - 更多科室
工具
服务